OLOKER – FROM THE BENCH TO THE BEDSIDE.
The case of cells called CPCPlus, endowed with impressive therapeutic potential, which can be transformed into a new pharmaceutical product indicated in refractory angina.
In just a few years, Oloker, the start-up created to treat the most serious forms of cardiac ischemia, is reaping the first results.
It all starts with a patent on CPCPlus (Cardiac Pro-angiogenic Cell Plus), a therapeutic method developed after 10 years of research, aimed at the isolation of a subtype of human heart stromal cells (CD90 negative), capable of inducing neo-vascularization .
This research was conducted by the Monzino Cardiology Center and the University of Milan. #Oloker #CPCPlus #angina
OLOKER – FROM THE BENCH TO THE BEDSIDE.
We are excited to take you on a brief journey through time to show where Oloker Therapeutics comes from and how incredibly it is progressing in the health field.
Born from the combination of scientific innovation and the desire to make a difference, OLOKER aims at providing treatment to patients who suffer from Refractory Angina, a chronic cardiovascular disease, which currently has no definitive treatment.
Through years of intensive research, we have developed an innovative technology to isolate a specific type of cells called CPCPlus, with an impressive therapeutics potential that can turn into a novel drug product for refractory angina, to improve the quality of life.
Watch the video that tells our story, OLOKER’s passion and dedication, the investment in the world of cardiovascular medicine.
full video link: https://lnkd.in/d6R7iVqs
#CellTherapy #cardiovasculardisease #disruptivetechnology
#fromBenchtoBedside
#Oloker
Director of Medicinal Chemistry | Drug-Discovery | Organic Synthesis | Drug-Development | Oncology
2moThis news is truly wonderful for both the industry and the patients who rely on it!